Scribe Therapeutics Wins TGA Clearance to Begin First Human Trial of STX-1150, a CRISPR Epigenetic Therapy Targeting PCSK9
Scribe's ELXR platform silences PCSK9 in the liver without cutting DNA; a single low dose sustained LDL reductions for roughly 18 months in primates.
6 min read5 sources